AI
ANIK icon

Analytic Investors’s Anika Therapeutics ANIK Stock Holding History

Analytic Investors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-10,156
Closed -$335K – 552
2015
Q2 		$335K Sell
10,156
-20,343
-67% -$726K ﹤0.01% 504
2015
Q1 		$1.26M Buy
+30,499
New +$1.23M 0.02% 335

Other funds holding ANIK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
LCP
Lombardia Capital Partners Pasadena, California $110M AUM 13.11% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

Analytic Investors's ANIK Position: Q3 2015 in Review

Analytic Investors sold out of Anika Therapeutics (ANIK) in Q3 2015, closing a stake of 10,156 shares — an estimated $335K sold.

Analytic Investors first reported a position in ANIK in Q1 2015 and held it in 2 quarters. The position peaked at $1.26M in Q1 2015. 138 funds tracked by Wall St. Rank hold ANIK as of Q3 2015.

  • Analytic Investors reported no remaining Anika Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Analytic Investors sold 10,156 Anika Therapeutics shares in Q3 2015, an estimated $335K.
  • Analytic Investors first reported a position in Anika Therapeutics in Q1 2015 and held it in 2 quarters.
  • Analytic Investors's Anika Therapeutics position peaked at $1.26M in Q1 2015.
  • 138 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2015.

Based on Analytic Investors's 13F filing for Q3 2015, filed 12 Nov 2015.